Table 4.

Treatment-related adverse events of vindesine-based regimens.

Adverse events	vAD (n = 77)	vDD (n = 35)	P-value
Hematologic events (Grade 3/4)	16 (20.8%)	12 (34.3%)	0.126
Neutropenia	11(14.3%)	11 (31.4%)	0.034
Thrombocytopenia	2 (2.6%)	1 (2.9%)	0.937
Anemia	3 (3.9%)	0 (0.0%)	0.237
Cardiotoxicity	8 (10.4%)	5 (14.3%)	0.551
Arrhythmia	5 (6.5%)	2 (5.7%)	0.875
Heart failure	2 (2.6%)	3 (8.6%)	0.156
Left ventricular systolic dysfunction	1 (1.3%)	0 (0.0%)	0.498
Infection	19 (24.7%)	18 (51.4%)	0.005
Pneumonia	16 (20.8%)	17 (48.6%)	0.003
Urinary tract	3 (3.9%)	1 (2.9%)	0.784
Thromboembolism	0 (0.0%)	0 (0.0%)	–
Deep vein thrombosis	0 (0.0%)	0 (0.0%)	–
Pulmonary embolus	0 (0.0%)	0 (0.0%)	–
Gastrointestinal	21 (27.3%)	5 (14.3%)	0.131
Vomiting	1 (1.3%)	1 (2.9%)	0.564
Diarrhea	5 (6.5%)	1 (2.9%)	0.428
Constipation	12 (15.6%)	3 (8.6%)	0.312
Intestinal obstruction	3 (3.9%)	0 (0.0%)	0.237
Hepatic disorders	4 (5.2%)	0 (0.0%)	0.170
Skin	5 (6.5%)	2 (5.7%)	0.875
Herpes zoster	1 (1.3%)	2 (5.7%)	0.180
Rash	4 (5.2%)	0 (0.0%)	0.170
Peripheral neuropathy	10 (13.0%)	2 (5.7%)	0.249